Targeting the TGFβ signaling pathway holds promising therapeutic implications in AD treatment due to its involvement in various aspects of the pathology, including neuroinflammation, synaptic dysfunction, and Aβ deposition. Here, TGFB1 is linked to Alzheimer disease.